568 XTX201, a protein-engineered IL-2, exhibits tumor-selective activity in mice without peripheral toxicities in non-human primates

• Wilson Guzman,
• Minjie Zhang,
• Parker Johnson,
• Megan McLaughlin,
• Kurt Jenkins,
• Hsin-Jung Wu,
• Hanumantha Rao Madala,
• Caitlin O’Toole,
• Magali Pederzoli-Ribeil,
• Raphael Rozenfeld,
• Huawei Qiu,
• Margaret Karow,
• Tim Clackson,
• Ronan O’Hagan,
• Jennifer O’Neil,
• Ugur Eskiocak

Affiliations

Wilson Guzman

Aff168 grid.467308.e0000 0004 0412 6436EMD Serono Billerica MA USA

Minjie Zhang

Xilio Therapeutics, Waltham, MA, USA

Parker Johnson

Xilio Therapeutics, Waltham, MA, USA

Megan McLaughlin

Xilio Therapeutics, Waltham, MA, USA

Kurt Jenkins

Xilio Therapeutics, Waltham, MA, USA

Hsin-Jung Wu

Xilio Therapeutics, Waltham, MA, USA

Hanumantha Rao Madala

Xilio Therapeutics, Waltham, MA, USA

Caitlin O’Toole

Xilio Therapeutics, Waltham, MA, USA

Magali Pederzoli-Ribeil

Xilio Therapeutics, Waltham, MA, USA

Raphael Rozenfeld

Xilio Therapeutics, Waltham, MA, USA

Huawei Qiu

Xilio Therapeutics, Waltham, MA, USA

Margaret Karow

Xilio Therapeutics, Waltham, MA, USA

Tim Clackson

Xilio Therapeutics, Waltham, MA, USA

Ronan O’Hagan

Xilio Therapeutics, Waltham, MA, USA

Jennifer O’Neil

Xilio Therapeutics, Waltham, MA, USA

Ugur Eskiocak

Xilio Therapeutics, Waltham, MA, USA